

**PRESCRIPTION ANIMAL REMEDY
KEEP OUT OF REACH OF CHILDREN
FOR ANIMAL TREATMENT ONLY**

Noroclox 500

DRY COW INTRAMAMMARY SUSPENSION

PRESENTATION

NOROCLOX 500 is a stable intramammary suspension prepared under sterile conditions. Each single dose 4.5 g syringe contains 500 mg cloxacillin (as the benzathine salt) in a long acting base with 3% aluminium stearate. Benzathine cloxacillin is a semi synthetic penicillin derived from 6 aminopenicillanic acid.

USES

NOROCLOX 500 is formulated for the treatment of subclinical mastitis caused by organisms sensitive to cloxacillin in dairy cows at drying off.

NOROCLOX 500 is active against gram positive organisms associated with mastitis and is effective against *Streptococcus agalactiae*, *Streptococcus dysgalactiae* and other streptococci and *Arcanobacterium pyogenes*. As cloxacillin is not destroyed by staphylococcal penicillinase, NOROCLOX 500 is active against penicillin resistant staphylococci which are an important cause of bovine mastitis.

NOROCLOX 500 contains benzathine cloxacillin in a long acting aluminium stearate base. NOROCLOX 500 is bactericidal in action and is non-irritant in the udder tissue.

DIRECTIONS FOR USE

Restraints:

DO NOT USE in lactating cows or within 30 days of calving.

Precautions:

If NOROCLOX 500 is accidentally administered to a lactating animal or within 30 days of calving, contact the prescribing veterinarian for advice.

Avoid use in cows that are allergic to penicillin.

Rubber gloves should be worn when infusing the suspension.

Infuse the contents of one syringe into each quarter after the final milking before drying off. The cow should be milked out normally and the teats cleaned and disinfected before infusion with the antibiotic.

NOROCLOX 500 is presented in syringes with a **variable tip**. This variable tip allows for either full or partial insertion into the teat orifice. Partial insertion only is preferable, as it may prevent unnecessary damage to the teat orifice. Full insertion will be needed for large teat orifices.

There is evidence that partial insertion can reduce the incidence of *Staphylococcus aureus* and *Streptococcus uberis* infections (Boddie *et al*, 1990).



Standard Syringe Tip



Variable Syringe Tip

It is normally unnecessary and undesirable to introduce any further treatment during the dry period. Cows having a very short dry period of 30 days or less should not be treated as after calving, milk will contain antibiotic residues.

Any variation by the prescribing veterinarian to the approved dose, frequency, duration, route, disease or target species may require extending the withholding period.

WITHHOLDING PERIODS

MEAT: DO NOT USE less than 30 days before slaughter for human consumption.

MILK: DO NOT USE in lactating cows or within 30 days of calving. After calving, colostrum or milk from treated dry cows **MUST NOT BE USED** for human consumption or processing for 96 hours (8 milkings). If premature or unscheduled calving occurs, consult the prescribing veterinarian for advice on handling milk for bobby calves.

TRADE ADVICE

EXPORT SLAUGHTER INTERVAL (ESI): This product does not have an ESI established. For advice on the ESI, contact the manufacturer on 1800 665 866 before using this product.

FIRST AID

If poisoning occurs, contact a doctor or Poisons Information Centre. Phone Australia 131126.

Manufactured by:

Norbrook Laboratories Limited, United Kingdom

Distributed by:

Norbrook Laboratories Australia Pty Limited
ACN 080 972 596
Unit 7/15- 21 Butler Way, Tullamarine, VIC 3043
Free call: 1800 665 866

DISPOSAL

Dispose of empty container by wrapping with paper and putting in garbage.

STORAGE

Store below 25°C (Air Conditioning). Protect from light.

APVMA Approval No.: 56978/0909

PRESENTATION

NOROCLOX 500 is packaged in individual dose 4.5 g intramammary syringes and is available in cartons of 20 syringes and buckets of 200 syringes.

